A detailed history of Driehaus Capital Management LLC transactions in Glaukos Corp stock. As of the latest transaction made, Driehaus Capital Management LLC holds 861,607 shares of GKOS stock, worth $130 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares
861,607
Previous 803,650 7.21%
Holding current value
$130 Million
Previous $95.1 Million 18.02%
% of portfolio
1.1%
Previous 1.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$113.62 - $135.39 $6.59 Million - $7.85 Million
57,957 Added 7.21%
861,607 $112 Million
Q2 2024

Aug 14, 2024

BUY
$89.48 - $118.35 $13.9 Million - $18.4 Million
155,653 Added 24.02%
803,650 $95.1 Million
Q1 2024

May 15, 2024

BUY
$76.4 - $96.33 $4.52 Million - $5.7 Million
59,144 Added 10.04%
647,997 $61.1 Million
Q4 2023

Feb 14, 2024

BUY
$59.53 - $85.11 $5.91 Million - $8.45 Million
99,288 Added 20.28%
588,853 $46.8 Million
Q3 2023

Nov 14, 2023

BUY
$69.23 - $79.09 $88,822 - $101,472
1,283 Added 0.26%
489,565 $36.8 Million
Q2 2023

Aug 14, 2023

BUY
$45.44 - $71.21 $22.2 Million - $34.8 Million
488,282 New
488,282 $34.8 Million
Q4 2019

Feb 12, 2020

SELL
$54.18 - $65.64 $2.84 Million - $3.44 Million
-52,398 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$58.58 - $83.91 $792,938 - $1.14 Million
13,536 Added 34.83%
52,398 $3.28 Million
Q2 2019

Aug 14, 2019

SELL
$63.59 - $78.71 $53,860 - $66,667
-847 Reduced 2.13%
38,862 $2.93 Million
Q1 2019

May 15, 2019

BUY
$50.75 - $80.54 $12,027 - $19,087
237 Added 0.6%
39,709 $3.11 Million
Q4 2018

Feb 14, 2019

BUY
$52.18 - $67.93 $981,088 - $1.28 Million
18,802 Added 90.96%
39,472 $2.22 Million
Q3 2018

Nov 14, 2018

BUY
$38.13 - $68.37 $788,147 - $1.41 Million
20,670 New
20,670 $1.34 Million

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $7.18B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.